Skip to main content
Continuing Education - Continuing Professional Development for Today's Healthcare Professionals
  •  

Psychotropic New Drug Update 1 • 38th Psychiatric Pharmacotherapy Update


Header showing Dr. Saklad and links to the 38th Psychiatric Pharmacotherapy Update

A FREE SNEAK PEEK at This Year's Psychiatric Pharmacotherapy Update

Welcome to a premier interprofessional gathering of mental health leaders! We are thrilled to have you join us for a dedicated exploration of advanced psychiatric pharmacotherapy.

This year we are adding FREE addtional BONUS CE webinar.  No 38th Psychiatric Pharmacotherapy Udpate registration required (live only).  But don't miss out!  Register here for the 38th Psychiatric Pharmacotherapy Udpate taking place on October 22-23 in Austin, Texas and Online - register for the October Update here. 
 
Webinar Instructions
 
How to Tune In
Live Zoom Webinar link below
 
Topic:  Psychotropic New Drug Updates
Join from PC, Mac, iPad, or Android:
https://utexas.zoom.us/j/82460266134 Zoom Meeting ID: 824 602 66134
Phone one-tap:  +13462487799,,82460266134# US (Houston)
 
 
2026 Psychotropic New Drug Update 1
This program will be a bonus webinar held during July 2026 with the final date still TBD
 
Learning Objectives 
  • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.
  • Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years.
 
Faculty
 
Stephen R. Saklad, Pharm.D., BCPP
Clinical Professor (Retired)
The University of Texas at Austin College of Pharmacy  
Division of Pharmacotherapy, UT Health San Antonio, Joe R. & Teresa Lozano Long School of Medicine
Pharmacotherapy Education and Research Center  
 
Dr. Saklad is a Clinical Professor at The University of Texas College of Pharmacy and a Pharmacist at San Antonio State Hospital since 1979. He has focused his career on clinical care, teaching, and research to improve the quality of life and function in the seriously and persistently mentally ill. He helped to create a clinical research unit at San Antonio State Hospital and developed the first websites for The University of Texas College of Pharmacy and the College of Psychiatric and Neurologic Pharmacists (CPNP). He is the Director of the University of Texas Psychiatric Pharmacy Program in San Antonio, having trained over 70 advanced practice pharmacists in psychiatric pharmacy. Dr. Saklad is a Founding Member of CPNP, served on the CPNP Board of Directors, and was the founding senior editor of their peer-reviewed journal, the Mental Health Clinician. He has published articles and presented to many groups around the country on a variety of pharmacy and mental health-related topics. He is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, and other serious mental illnesses, as well as their pharmacokinetics and interactions. He has received several honors, most recently the Judith J. Saklad Memorial Award from CPNP in 2012 and the Teaching Excellence Award from the UT College of Pharmacy in 2013.
 
Disclosure: Dr. Stephen Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
Speakers Bureau: Bristol Myeers Squibb, Luye, Otuska PsychU, Nerocrine, Teva
Consultant: Alkermes, Bristol Myeers Squibb,Genomind, Janssen, Lundbeck, Otuska

Mitigation: The University of Texas at Austin College of Pharmacy event planning committees reviewed the relationships and determined there was no connection between presentations and disclosed relationships.

 
 

Date: Oct 7, 2026 12:00 PM - 01:00 PM

Fee

$0.00

CE Hours

1.00

CE Units

0.100

Registration closes on Oct 07, 2026 10:00 PM

Activity Type

Knowledge

Support

CME: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education(ACCME) through the joint providership of the Texas AM University Naresh K. Vashisht College of Medicine and University of Texas at Austin College of Pharmacy to provide continuing medical education for physicians.

Texas A&M University Naresh K. Vashisht College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

 Stephen R. Saklad, PharmD, BCCP , faculty for this educational activity has disclosed the following relationships: consultant for Alkermes, BMS, Genomind, Janssen, Lundbeck, and Otsuka. He is also on the speakers bureau for BMS, Luye, Otsuka PsychU, Neurocrine, and Teva.  

All of the relevant financial relationships listed have been mitigated.

The following planners have disclosed the following relationships:

  • Stephen R. Saklad, PharmD, BCCP has disclosed the following relationships: consultant for Alkermes, BMS, Genomind, Janssen, Lundbeck, and Otsuka. He is also on the speakers bureau for BMS, Luye, Otsuka PsychU, Neurocrine, and Teva.  
  • Manish Kumar Jha, MD, MBBS has disclosed the following relationships: consultant for Janssen and Nuerocrine, and received research grants from Navitor/Supernus.

All of the relevant financial relationships listed have been mitigated.

The other planners for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

CPE: 

ACPE logo for CPE creditThe University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This online activity is approved for 0.10 CEUs (1.00 contact hours) of continuing education credit. To receive 1.00 contact hours of CE credit, the participant must watch the included webinar in its entirety. Upon successfully completing the course evaluation.

CNE: 

Coming soon

Social Work / Counselors / APA:

The Office of Professional Development at The University of Texas at Austin Steve Hicks School of Social Work provides continuing education in accordance with the criteria and standards of the Texas Board of Social Workers, Licensed Professional Counselors, and Licensed Marriage and Family Therapists and Licensed Psychologist under Texas Administrative Code, Title 22, Part 34. § 781.509. Complaints about this program may be made to TSBSWE, 333 Guadalupe St., Tower 3, Room 900, Austin, TX 78701 • 512-305-7700 • 800-821-3205 • bhec.texas.gov/texas-state-board-of-social-worker-examiners/ -Peer Counselor / Addition Counselor Provider Number: 2050-20
 

 

2026 Psychotropic New Drug Update 1
   

2026 Psychotropic New Drug Update 1
 
After the webinar - click on the green "Complete Evaluation" button for CE Credit - NOTE the button will only appear starting at noon CT Oct 7. 
 
Learning Objectives 
  • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.
  • Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years.
 
Faculty
 
Stephen R. Saklad, Pharm.D., BCPP
Clinical Professor (Retired)
The University of Texas at Austin College of Pharmacy  
Division of Pharmacotherapy, UT Health San Antonio, Joe R. & Teresa Lozano Long School of Medicine
Pharmacotherapy Education and Research Center  
 
Dr. Saklad is a Clinical Professor at The University of Texas College of Pharmacy and a Pharmacist at San Antonio State Hospital since 1979. He has focused his career on clinical care, teaching, and research to improve the quality of life and function in the seriously and persistently mentally ill. He helped to create a clinical research unit at San Antonio State Hospital and developed the first websites for The University of Texas College of Pharmacy and the College of Psychiatric and Neurologic Pharmacists (CPNP). He is the Director of the University of Texas Psychiatric Pharmacy Program in San Antonio, having trained over 70 advanced practice pharmacists in psychiatric pharmacy. Dr. Saklad is a Founding Member of CPNP, served on the CPNP Board of Directors, and was the founding senior editor of their peer-reviewed journal, the Mental Health Clinician. He has published articles and presented to many groups around the country on a variety of pharmacy and mental health-related topics. He is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, and other serious mental illnesses, as well as their pharmacokinetics and interactions. He has received several honors, most recently the Judith J. Saklad Memorial Award from CPNP in 2012 and the Teaching Excellence Award from the UT College of Pharmacy in 2013.
 
Disclosure: Dr. Stephen Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
Speakers Bureau: Bristol Myeers Squibb, Luye, Otuska PsychU, Nerocrine, Teva
Consultant: Alkermes, Bristol Myeers Squibb,Genomind, Janssen, Lundbeck, Otuska

Mitigation: The University of Texas at Austin College of Pharmacy event planning committees reviewed the relationships and determined there was no connection between presentations and disclosed relationships.

 
 

Activity Number

0067-0000-26-108-L01-P/T
Date: 10/07/26
Time: 12:00 PM - 01:00 PM

CE Hours

1.00
   

Register Today for the 38th Psychiatric Pharmacotherapy Update

More information about the 38th Psychiatric Pharmacotherapy Update
   

THIS IS JUST THE BEGINNING
 
Dr. Saklad's Part 2 drug update drops in November, but it's exclusive to registrants of the 38th Annual Psychiatric Pharmacotherapy Update, October 22–23 in Austin (or online, live or on-demand).
 
Why wait? Lock in your spot now for:
 
  • Up to 14 hours of CE credit
  • Optional 10-credit CPD pathway for pharmacists
  • Nationally recognized faculty covering polypharmacy, postpartum psychosis, AI in mental health, buprenorphine, and more
  • Your choice: in-person in Austin, live online, or on-demand
 
 
38 Years of Excellence. Advanced Neuroscience. Advanced Psychopharmacology. Real-World Patient Care.
 
 
Overview
 
Psychiatric Pharmacotherapy Update logoThe 2026 Psychiatric Pharmacotherapy Update offers 14+ hours of high-level, evidence-based continuing education (CPE, CME, CNE, APA, and Social Work). This interprofessional seminar focuses on "Serious Science," providing clinicians with the most rigorous and timely data to improve the quality of care for patients with mental health disorders.
 
Our 2026 curriculum explores the frontiers of neuropsychiatry, moving beyond traditional boundaries to investigate the biological, technological, and systemic factors impacting modern practice. All sessions are recorded and will be released in our on-demand video library in late November.
 
2026 Clinical Pillars
 
This year's program features a diverse range of topics curated for the practicing clinician:
  • Emerging Science & Technology: Explore the Role of Inflammation in psychiatric disorders, the integration of AI in Mental Health, and the "missing piece" of Nutritional Psychiatry.
  • Complex Management: Deep dives into the Consensus Taskforce on Psychotropic Polypharmacy, the management of Acute Aggression and Agitation in Serious Mental Illness (SMI), and strategies for Disruptive Behaviors in ADHD.
  • Lifespan & Hormonal Health: Expert sessions on Hormonal Transitions and Mental Health, as well as specialized considerations for the Geriatric Population, including mood disorders and the management of Schizophrenia in older adults.
  • Pharmacotherapeutic Frontiers: Updates on Buprenorphine for chronic pain and opioid dependence, the evolving role of GLP-1 Therapies from metabolic health to substance use disorders, and a critical look at Psychopharmacology Facts vs. Myths.
 
Target Audience
 
This seminar is designed for pharmacists, psychiatrists, physicians, nurses, physician assistants, psychologists, and social workers who specialize in or have an interest in neuropsychiatric disorders and wish to master the latest clinical advances.